Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Update

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the target of a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 29,679 shares, a decline of 85.5% from the July 30th total of 205,218 shares. Approximately 6.3% of the company’s stock are short sold. Based on an average daily trading volume, of 85,940 shares, the short-interest ratio is presently 0.3 days.

Institutional Investors Weigh In On Jupiter Neurosciences

Several large investors have recently made changes to their positions in the company. Allen Capital Group LLC bought a new stake in shares of Jupiter Neurosciences during the 4th quarter worth about $31,000. Yorkville Advisors Global LP acquired a new stake in Jupiter Neurosciences in the 4th quarter worth approximately $135,000. Geode Capital Management LLC lifted its holdings in Jupiter Neurosciences by 27.8% in the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after purchasing an additional 28,826 shares during the last quarter. Finally, Vestor Capital LLC boosted its position in Jupiter Neurosciences by 144,607.2% during the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after purchasing an additional 970,314 shares during the period.

Jupiter Neurosciences Stock Down 2.4%

Jupiter Neurosciences stock traded down $0.12 during mid-day trading on Thursday, hitting $4.89. The company’s stock had a trading volume of 86,220 shares, compared to its average volume of 405,123. The stock has a market capitalization of $4.46 million, a P/E ratio of -0.26 and a beta of 1.98. Jupiter Neurosciences has a twelve month low of $4.56 and a twelve month high of $137.96. The stock’s fifty day moving average price is $10.73 and its two-hundred day moving average price is $22.43.

Jupiter Neurosciences (NASDAQ:JUNS) last released its quarterly earnings results on Friday, August 14th. The company reported ($5.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.75) by ($1.31). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.40 million.

Wall Street Analysts Forecast Growth

JUNS has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Wednesday, June 24th. Wall Street Zen upgraded Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.